Why plasma protein therapies are safe
Selection of starting material:
donor screening/donor exclusion
Your blood is: 55% plasma, 44% red blood cells, 1% white blood cells & platelets
National donor deferral registry
Current manufacturing protocols are highly effective against pathogens.
The industry has a record of safety from pathogens for more than 20 years.
Unlike traditional pharmaceuticals or other biologics plasma protein therapies’ safety protocols are constantly evolving due to new and emerging pathogens.
Companies must continuously perform tests to demonstrate that their viral inactivation and removal steps work on new pathogens. Most recently, companies invested significant time and resources into researching the Zika virus to ensure it does not threaten the safety of plasma protein therapies.